Cadence Molecular Sciences (OpenEye) – a business unit of Cadence (Nasdaq: CDNS) – announced today that Pfizer Inc. has signed an agreement to extend and expand access to Cadence’s OpenEye products and programming toolkits for advanced molecular design.
Read the full news release here.
For media inquiries, please contact newsroom@cadence.com